Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.

By V. Gondi, S. Pugh, W. Tomé, Chip Caine, B. Corn, A. Kanner, H. Rowley, V. Kundapur, A. Denittis, J. Greenspoon and 7 more. Journal of Clinical Oncology, 2014

1,051 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0dd5cd1f1699996cc47ece609c168752f1432841

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Planchard
2. P. Brown
3. V. Gondi
4. S. Popat
5. S. Pugh
6. K. Kerr
7. W. Tomé
8. S. Novello

Citations in the corpus

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Hippocampus avoidance WBRT has been shown to be probably safe [269], but is still undergoing trial evaluation and is not currently recommended for routine care [III, C].”
• Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. (2020, background): “To our knowledge, this trial provides the first definitive clinical evidence that the hippocampal neuroregenerative niche is important to pathophysiology of RT-induced cognitive decline and builds on extensive preclinical work and prior clinical studies.(9,10,12,13,27,28) This trial’s observation of”